Clinical Trials Browser

Phase 2 × Mesothelioma × tazemetostat × Clear all

NCT02860286 2021-04-09

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Phase 2 Completed

74 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma